



**EL DORADO COUNTY
PLANNING & BUILDING DEPARTMENT
ECONOMIC DEVELOPMENT DIVISION**

2850 Fairlane Court, Placerville, CA 95667
Phone (530) 621-5595

AmCyt

5175 Hillsdale Circle, Suite 155, El Dorado Hills, CA 95762
<https://amcyt.com>

FOUNDER(S): Alejandro Mendoza and Gary Wilson

Dr. Alejandro Mendoza possesses extensive expertise in pathology and cytopathology, combined with a strong passion for innovation. Meanwhile, Gary Wilson brings four (4) decades of experience in successfully bringing medical devices to market.

SECTOR: Research & Development

RECOMENDED AMOUNT: Up to \$50,000 provided in tranches based on milestones achieved.

USE OF FUNDS: Support the completion of beta product and contribute to testing and a targeted October 2024 commercial release of the product into the veterinary market. Deployment into the veterinary market will provide valuable data and revenue to support product and company growth while work is continued toward Unites States Food and Drug Administration (FDA) clearance and deployment into healthcare settings.

DESCRIPTION: AmCyt is a medical device company focused on creating a device that can quickly assess fine needle aspiration (FNA) biopsy samples at the location of the procedure. The device aims to offer prompt evaluation for determining sample adequacy and providing preliminary diagnostic information.

The scarcity of pathologists has created a demand for a rapid onsite evaluation (ROSE) service, as there is a shortage of professionals available to perform this manual procedure. In the absence of ROSE, there is a twenty (20) percent likelihood that patients will require a repeat biopsy procedure. Additionally, hospitals offering ROSE services face financial losses due to significant overhead costs. AmCyt's eROSE device can eliminate the need for an onsite pathologist during ROSE, making it affordable and easily accessible for on-demand use.

Implementing this system could save hospitals performing ten (10) to twenty (20) procedures per day up to four hundred thousand dollars (\$400,000) annually. Most importantly, it could prevent patients from experiencing delayed cancer diagnoses and the pain associated with repeat biopsy procedures. Eventually, hospitals could benefit from innovative cost saving solutions that improve patient care and outcomes.

GRANT ALIGNMENT:

- Strong founder fit with extensive expertise
- Partnership with local business for development of beta product
- Recipient of Small Business Innovation Research (SBIR) Phase 1 grant and pre-seed venturing funding to support Research & Development
- Potential for employee growth
- Local product manufacturing
- Innovative cost saving solutions and improved patient care and outcomes